✨ Free AI Report
Equillium, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Equillium, Inc.
Company Research

Equillium, Inc.: Business Overview, Financials & Competitive Analysis

Equillium is a clinical-stage biotechnology company developing therapeutics to treat severe autoimmune and inflammatory disorders with unmet medical need. The company focuses on immunobiology-driven approaches with a ...

Analyst-debate audio for Equillium, Inc.

AskCyborg analysts argue the bull and bear cases for Equillium, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Clinical-stage biotech with differentiated mechanism entering early human testing in 2026; success depends on EQ504...

Read the full analyst-debate transcript →
Industry Biotechnology - Clinical-Stage Immunology/Inflammation
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Equillium, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Equillium, Inc. Overview

Pro stress-test →

Equillium is a clinical-stage biotechnology company developing therapeutics to treat severe autoimmune and inflammatory disorders with unmet medical need. The company focuses on immunobiology-driven approaches with a lead candidate positioned to enter Phase 1 studies in mid-2026, aiming to establish clinical proof-of-concept in previously untreated therapeutic areas.

Strategic Profile

Pro stress-test →

The lead program, EQ504, is an aryl hydrocarbon receptor (AhR) modulator designed with a non-immunosuppressive mechanism of action that maintains barrier function and promotes tissue repair while regulating resident immune cells. Recent $50M financing extends cash runway through 2027, positioning the company to advance EQ504 and validate its differentiated immunology platform in multiple indications.

Competitive Landscape

Pro stress-test →

Equillium competes in the crowded immunomodulation space against larger, better-capitalized competitors developing JAK inhibitors, anti-TNF biologics, and other inflammation modulators. Differentiation rests on AhR-based mechanism and non-immunosuppressive approach for barrier organ diseases, a relatively underpenetrated niche within severe immune-inflammatory disorders.

Industry Context

Equillium, Inc. operates in Biotechnology - Clinical-Stage Immunology/Inflammation.

Key facts

Founded: 2017 · Headquarters: La Jolla, California

What the analysts stress-tested

The top findings that survived the multi-agent debate for Equillium, Inc..

  • Lead candidate EQ504 entering Phase 1 proof-of-mechanism study in mid-2026 with six-month readout timeline
  • August 2025 $50M financing from tier-one biotech investors (ADAR1, Janus Henderson, Adage Capital) signals external validation of platform
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 2025Announced $50M financing to accelerate EQ504 clinical development with Phase 1 start planned for mid-2026
  • November 2025Q3 2025 results reported; operational update confirming $30M initial tranche funding through 2027
  • +1 moreTrack every material event for Equillium, Inc. as it happens. Explore monitoring →
Get alerted when Equillium, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

JAK Inhibitors (baricitinib, upadacitinib)Established oral immunosuppressants for autoimmune/inflammatory conditions→Anti-TNF biologics (adalimumab, infliximab)Market-leading monoclonal antibodies for inflammatory bowel disease and systemic autoimmunity→Ozanimod, vedolizumabSelective immunomodulators targeting specific lymphocyte trafficking and adhesion pathways→

Compare Equillium, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Equillium, Inc. operates in Biotechnology - Clinical-Stage Immunology/Inflammation. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Clinical-Stage Immunology/Inflammation research →
NEW · MCP server

Ask your AI assistant about Equillium, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Equillium, Inc. and its top competitor on Cyborg Score”
“What did Equillium, Inc. do this quarter?”
“Is Equillium, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Equillium, Inc. do?+
Equillium is a clinical-stage biotechnology company developing therapeutics to treat severe autoimmune and inflammatory disorders with unmet medical need. The company focuses on immunobiology-driven approaches with a ...
What is Equillium, Inc.'s Cyborg Score?+
Equillium, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Equillium, Inc.'s main competitors?+
Named competitors include JAK Inhibitors (baricitinib, upadacitinib), Anti-TNF biologics (adalimumab, infliximab), Ozanimod, vedolizumab. The full competitive landscape is in the AskCyborg report.
How can I get the full Equillium, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Equillium, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Equillium, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.